Pfizer shares surge 7.5% after profit rises 27% in June quarter

Shares of Pfizer Ltd, the multinational drugmaker, were in high demand in trade on Thursday, August 14, a day after it reported its April-June quarter earnings. The stock rose as much as 7.5% to hit an intraday high of ₹5,510 on the BSE. On the National Stock Exchange, Pfizer shares rose as much as 8% to hit an intraday high of ₹5,513.50.

Pfizer, post market hours on Wednesday, reported a net profit of ₹192 crore in the first quarter of the current financial year (Q1FY26), marking an increase of 27% from ₹151 crore in the same period last year.

Pfizer's revenue from operations rose 7% to ₹603 crore in the April-June period from ₹563 crore in the year-ago period.

The company posted strong operational performance, as its EBITDA (earnings before interest, taxes, depreciation, and amortisation), also known as operating profit, rose 18% to ₹209 crore from ₹178 crore in the corresponding period last year.

"During the quarter ended March 31, 2025, the Company had received requisite approvals from MIDC to assign and assume the lease of MIDC land and the sale of the building constructed on such land and has completed the transfer and sale of said assets. Net gain of ₹172.81 crore (net of carrying value of ₹31.75 crore and cost to sell – premium and other charges of ₹59.84 crore, net of recovery) is disclosed as an 'Exceptional item' in the financial results," Pfizer said in a regulatory filing.

Earlier this week, Pfizer informed exchanges that it launched 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India. The vaccine is indicated for protection against pneumococcal disease in adults.

"Pfizer’s vaccine helps protect against 20 clinically relevant serotypes responsible for a majority of invasive and non-invasive pneumococcal disease. It enables timely and proactive protection for all adults, including those living with chronic conditions. PCV20 will be available as a single-shot vaccine, and those vaccinated with PCV20 may not need a second dose," the company said.

Meanwhile, Pfizer shares were witnessing heavier than usual trading volumes on Thursday as trading volume spiked by 18 times to 3.22 lakh shares compared with an average trading volume of 17,755 shares.

On the BSE, as many as 19,000 shares changed hands as against an average of 1,092 shares traded daily in the past two weeks.

As of 1:03 pm, Pfizer shares traded 4.22% higher at ₹5,342, outperforming the BSE 500 index, which was trading on a flat note.